İlknur SUER

Dr. İlknur SUER

orcid

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 June 2014 in PLOS ONE
Verified
Journal Article
Open access
PDF file
OKOmer Faruk Karatas
Omer Faruk Karatas
ETEsra Guzel Tanoglu
Esra Guzel Tanoglu
İSİlknur SUER
İlknur SUER
IEIsin D. Ekici
Isin D. Ekici
TCTurhan Caskurlu
Turhan Caskurlu
MOMustafa Ozen
Mustafa Ozen
Prostate cancer (PCa) is currently the most frequently diagnosed malignancy in the western countries. It is more prevalent in older men with 75% of the incident cases above 65 years old. After radical prostatectomy, approximately 30% of men develop clinical recurrence with elevated serum prostate-specific antigen levels. Therefore, it is important to unravel the molecular mechanisms underlying PCa progression to develop novel diagnostic/therapeutic approaches. In this study, it is aimed to compare the microRNA (miRNA) profile of recurrent and non-recurrent prostate tumor tissues to explore the possible involvement of miRNAs in PCa progression. Total RNA from 41 recurrent and 41 non-recurrent PCa tissue samples were used to investigate the miRNA signature in PCa specimens. First of all, 20 recurrent and 20 non-recurrent PCa samples were profiled using miRNA microarray chips. Of the differentially expressed miRNAs, miR-1, miR-133b and miR-145* were selected for further validation with qRT-PCR in a different set of 21 recurrent and 21 non-recurrent PCa samples. Data were statistically analyzed using two-sided Student's t-test, Pearson Correlation test, Receiver operating characteristic analysis. Our results demonstrated that miR-1 and mir-133b have been significantly downregulated in recurrent PCa specimens in comparison to non-recurrent PCa samples and have sufficient power to distinguish recurrent specimens from non-recurrent ones on their own. Here, we report that the relative expression of miR-1 and mir-133b have been significantly reduced in recurrent PCa specimens in comparison to non-recurrent PCa samples, which can serve as novel biomarkers for prediction of PCa progression.

22 October 2015 in Tumor Biology
Verified
Journal Article
Closed access
PDF file
OKOmer Faruk Karatas
Omer Faruk Karatas
İSİlknur SUER
İlknur SUER
BYBetul Yuceturk
Betul Yuceturk
MYMehmet Yilmaz
Mehmet Yilmaz
YHYusif Hajiyev
Yusif Hajiyev
MOMustafa Ozen
Mustafa Ozen

17 October 2014 in Head & Neck
Verified
Journal Article
Closed access
PDF file
OKOmer Faruk Karatas
Omer Faruk Karatas
BYBetul Yuceturk
Betul Yuceturk
İSİlknur SUER
İlknur SUER
MYMehmet Yilmaz
Mehmet Yilmaz
HCHarun Cansiz
Harun Cansiz
MOMustafa Ozen
Mustafa Ozen

21 October 2018 in The Prostate
Verified
Journal Article
Closed access
PDF file
İSİlknur SUER
İlknur SUER
ETEsra Guzel Tanoglu
Esra Guzel Tanoglu
OKOmer F. Karatas
Omer F. Karatas
CCChad J. Creighton
Chad J. Creighton
MIMichael Ittmann
Michael Ittmann
MOMustafa Ozen
Mustafa Ozen

1 April 2014 in Current Stem Cell Research & Therapy
Verified
Journal Article
Closed access
PDF file
İSİlknur SUER
İlknur SUER
OKOmer Faruk Karatas
Omer Faruk Karatas
BYBetul Yuceturk
Betul Yuceturk
MYMehmet Yilmaz
Mehmet Yilmaz
GGGulgun Guven
Gulgun Guven
MOMustafa Ozen
Mustafa Ozen
Larynx cancer (LCa) is an aggressive malignancy, which is the second most common malignant neoplasm of head and neck squamous cell carcinoma. Its incidences have been reported to increase and therapeutic options mostly fail to give positive clinical response especially for the advanced LCa cases. In this study we aimed to isolate stem-like cells from freshly resected LCa tumor specimens and characterize them by quantitative real time PCR (qRT-PCR) for expression of cancer stem cell markers including SOX2, OCT4, KLF4, ABCG2, CXCR4 and CD44. Our results showed that CD133(high) cells directly isolated from freshly resected tumor specimens exhibit elevated levels of SOX2, OCT4 and KLF4, and have increased expression levels of ABCG2 and CXCR4, which were associated with resistance of tumors to regular chemotherapeutic reagents. In conclusion, this study offers a useful approach utilizing CD133 to isolate stem cells directly from fresh tissues, which gives the opportunity to develop novel therapeutic tools specifically targeting these cells through their further characterization.

5 November 2016 in BMC Cancer
Verified
Journal Article
Open access
PDF file
OKOmer Faruk Karatas
Omer Faruk Karatas
İSİlknur SUER
İlknur SUER
BYBetul Yuceturk
Betul Yuceturk
MYMehmet Yilmaz
Mehmet Yilmaz
BOBuge Oz
Buge Oz
MOMustafa Ozen
Mustafa Ozen
Emerging evidences proposed that microRNAs are associated with regulation of distinct physio-pathological processes including development of normal stem cells and carcinogenesis. In this study we aimed to investigate microRNA profile of cancer stem-like cells (CSLCs) isolated form freshly resected larynx cancer (LCa) tissue samples. CD133 positive (CD133+) stem-like cells were isolated from freshly resected LCa tumor specimens. MicroRNA profile of 12 pair of CD133+ and CD133− cells was determined using microRNA microarray and differential expressions of selvected microRNAs were validated by quantitative real time PCR (qRT-PCR). MicroRNA profiling of CD133+ and CD133− LCa samples with microarray revealed that miR-26b, miR-203, miR-200c, and miR-363-3p were significantly downregulated and miR-1825 was upregulated in CD133+ larynx CSLCs. qRT-PCR analysis in a total of 25 CD133+/CD133− sample pairs confirmed the altered expressions of these five microRNAs. Expressions of miR-26b, miR-200c, and miR-203 were significantly correlated with miR-363-3p, miR-203, and miR-363-3p expressions, respectively. Furthermore, in silico analysis revealed that these microRNAs target both cancer and stem-cell associated signaling pathways. Our results showed that certain microRNAs in CD133+ cells could be used as cancer stem cell markers. Based on these results, we propose that this panel of microRNAs might carry crucial roles in LCa pathogenesis through regulating stem cell properties of tumor cells.